Pmv Pharmaceuticals, Inc. · NASDAQ:PMVP
Pmv Pharmaceuticals — Investor Presentation (September 2026)
27 slides from Pmv Pharmaceuticals's investor presentation, September 2026
Slide 1: PMV Pharmaceuticals
PMV Pharmaceuticals September 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for rezatapopt, including the timing of disclosures reg
Slide 3: PMV Pharma is Harnessing the Power of p53 to Treat Cancer
PMV Pharma is Harnessing the Power of p53 to Treat Cancer The Science Rezatapopt, our lead candidate, is a first-in-class, investigational p53 Y220C reactivator, a previously undruggable target found in 3.2% of ovarian cancers and 1% of all solid tumors Clinical Validation Phase 1 PYNNACLE achieved
Slide 4: Rezatapopt Targets TP53 Y220C Hotspot Mutation Detected Across Solid Tumors
Rezatapopt Targets TP53 Y220C Hotspot Mutation Detected Across Solid Tumors Frequencyofofthe Frequency theTP53 TP53Y220C Y220Cmutation mutation • TP53 mutations are the most common genomic varies varies across across solid solid tumors tumors 3 3–5 alterations across all human cancers1 • Most TP53 m
Slide 5: Rezatapopt is a p53 Y220C-Selective First-in-Class p53 Reactivator
Rezatapopt is a p53 Y220C-Selective First-in-Class p53 Reactivator • Orally available small molecule designed to selectively bind to the pocket contained in the p53 Y220C mutant protein 1 • Stabilizes the p53 Y220C mutant protein in the wild-type p53 conformation, thereby restoring transcription and
Slide 6: Compelling Rezatapopt Monotherapy Phase 2 Interim Data
Compelling Rezatapopt Monotherapy Phase 2 Interim Data Across All Cohorts: • Encouraging efficacy profile in heavily pre-treated patients with a TP53 Y220C mutation with poor prognoses 1 • TP53 Y220C mutation leads to • Promising rate of tumor responses observed across multiple tumor types a worse p
Slide 7: Overview of PYNNACLE Phase 2 Interim Data
Overview of PYNNACLE Phase 2 Interim Data Overall results across all cohorts Updated Ovarian cohort results NDA submission strategy Looking ahead 7
Slide 8: PYNNACLE Phase 2 Study Design
PYNNACLE Phase 2 Study Design Ongoing Phase 2 study actively enrolling patients across ~70 sites globally Cohorts Patient Population Cohort 1: Ovarian cancer Endpoints • Aged ≥ 12 years Primary: ORR per BICR - Ovarian cancer cohort • Locally advanced or metastatic solid Basket Cohort 2: Lung cancer
Slide 9: Demographics and Baseline Characteristics (All Cohorts)
Demographics and Baseline Characteristics (All Cohorts) Heavily pre-treated patients across broad spectrum of tumor types Total Cancer Type N=112 Head and neck cancer Other solid tumorsa Age (years) Median 65 Gallbladder cancer 1%, n=1 8%, n=9 1%, n=1 Sex Female 73%, Male 27% Ampullary carcinoma 2%,
Slide 10: Responses Observed Across All Cohorts in Eight Tumor Types
Responses Observed Across All Cohorts in Eight Tumor Types TP53 Y220C / KRAS WT Efficacy Population a (n=103) Across All Cohorts ORR n (%) By Cohort ORR n (%) ORR per Investigator assessment 35 (34%) Ovarian 22/48 (46%) Confirmed Complete Response (CR) 1 Breast 2/12 (17%) Confirmed Partial Response
Slide 11: Target Lesion Reduction Observed in the Majority of Patients
Target Lesion Reduction Observed in the Majority of Patients Including patients (n=92) with a post-baseline tumor assessment. Best overall responses are noted in the figure (* = uPR). Data Cutoff 04Sep2025 At the time of data cut, an additional uPR was recorded without tumor measurements reported ye
Slide 12: Rapid Time to Response and Long Duration of Treatment
Rapid Time to Response and Long Duration of Treatment 40% of patients remain on treatment All cohorts • Median TTR: 1.3 months • Median DoR: 7.6 months Ovarian cancer All other solid tumors Treatment ongoing CR PR uPR Months Data Cutoff 04Sep2025 CR, complete response; DoR, duration of response; PR,
Slide 13: Updated Ovarian Cancer Data
Updated Ovarian Cancer Data 13
Slide 14: Demographics and Baseline Characteristics
Ovarian Cancer Demographics and Baseline Characteristics Heavily pre-treated population with poor prognostic features Ovarian cancer cohort, n=76 Median age, years (min–max) 66 (46–91) ECOG performance status, n (%) 0/1 36 (47) / 40 (53) Prior lines of systemic therapy, n (%) Heavily pre-treated pat
Slide 15: Rezatapopt Demonstrates Consistent ~42-53% ORR Across Key Ovarian Subgroups
Ovarian Cancer Rezatapopt Demonstrates Consistent ~42-53% ORR Across Key Ovarian Subgroups Ovarian cancer Platinum Platinum Prior Prior FRα FRα cohort resistant refractoryb bevacizumab PARPi positive c negatived n=72a n=44 n=25 n=57 n=38 n=30 n=31 ORRe % 44 45 44f 44 53 50 42 CR 1 (1.4) 0 (0.0) 0 (0
Slide 16: Rezatapopt Demonstrates Deep Tumor Shrinkage in Ovarian Cancer
Ovarian Cancer Rezatapopt Demonstrates Deep Tumor Shrinkage in Ovarian Cancer *** Dotted line shows RECIST v1.1 criteria for PD (20%) and PR (–30%). Data Cutoff 29Mar2026 Includes ovarian cancer patients with a post-baseline target tumor measurement (n=63). Best overall responses are noted in the fi
Slide 17: Rapid and Durable Responses Were Observed in Ovarian Cancer
Ovarian Cancer Rapid and Durable Responses Were Observed in Ovarian Cancer ~40% of patients with ovarian cancer remain on treatment Median time to response Median duration of response 1.3 months 8.2 months Treatment ongoing (n=30) CR (n=1) PR (n=31) Start of uCR (n=3)a Start of uPR (n=2)b Data Cutof
Slide 18: Rezatapopt Displays Favorable Safety and Tolerability Profile in the Overall Population
Rezatapopt Displays Favorable Safety and Tolerability Profile in the Overall Population All TRAEs (≥ 5% of Patients) Total safety population (N=141) Maximum CTCAE gradea Patients, n (%) Preferred term Any grade 1 2 3 4 • TRAEs were mostly Grade 1 or 2 Nausea 59 (41.8) 41 (29.1) 18 (12.8) - - • Most
Slide 19: Rezatapopt On-target Activity Supported by Decreases in ctDNA TP53 Y220C VAF
Ovarian Cancer Rezatapopt On-target Activity Supported by Decreases in ctDNA TP53 Y220C VAF in Ovarian Cancer Patients Reduction in TP53 Y220C VAF was seen in most patients with ovarian cancer who had available data (n=55) • 55 patients had ctDNA TP53 Y220C VAF data available at baseline and on trea
Slide 20: Rezatapopt Maintains Durable, Consistent Efficacy Across Data Cuts with Deepening Responses
Ovarian Cancer Rezatapopt Maintains Durable, Consistent Efficacy Across Data Cuts with Deepening Responses • Consistent compelling ORR across data 14May2026 data cutoff N=76a cuts demonstrating sustained clinical benefit ORRb % 46% • Emerging complete responses, including [95% CI] [34.5-57.9] PR to
Slide 21: Ovarian Cancer Registration Strategy Supported by FDA
Ovarian Cancer Registration Strategy Supported by FDA Targeting 1Q2027 NDA submission seeking accelerated approval Orphan Drug Designation granted for rezatapopt in TP53 Y220C ovarian cancer Ovarian cohort Ovarian cohort Ovarian cohort enrollment progressing primary analysis data planned NDA submiss
Slide 22: Rezatapopt Offers Compelling Commercial Opportunity
Rezatapopt Offers Compelling Commercial Opportunity Commercial Opportunity: • De-risked opportunity in PROC as lead indication with projected 2027 launch • Clear value proposition for rezatapopt relative to existing and emerging treatments • TP53 Y220C mutation broadly identifiable • Potential to ex
Slide 23: Rezatapopt Well-Positioned for Success in Ovarian Cancer
Rezatapopt Well-Positioned for Success in Ovarian Cancer Platinum-Sensitive Patients Limitation of approved options: Platinum-based Chemotherapy • Chemotherapy offers limited efficacy • Inconvenient IV administration 1st Line 2nd Line 3rd Line • AEs requiring invasive monitoring • Potential for cumu
Slide 24: TP53 Y220C Mutation is Broadly Identifiable on Existing NGS Panels
TP53 Y220C Mutation is Broadly Identifiable on Existing NGS Panels Established partnership with Foundation Medicine to develop a CDx for rezatapopt • TP53 Y220C mutation is broadly identifiable across tissue and liquid biopsy assays • Molecular testing is recommended by NCCN and ESMO across many can
Slide 25: TP53 Y220C 2L+ Ovarian Cancer Offers Meaningful Market Potential
TP53 Y220C 2L+ Ovarian Cancer Offers Meaningful Market Potential Total 2L+ TP53 Y220C Ovarian Cancer ~1,900 ~$550 - 700M ~$850M – 1B Addressable 2L+ U.S. Market Global Market U.S. & EU4/UK Patients1 Potential2 Potential3 • Rezatapopt is a potential first-in-class therapy targeting TP53 Y220C, a biom
Slide 26: Future Opportunities to Grow Rezatapopt Beyond Ovarian Cancer
Future Opportunities to Grow Rezatapopt Beyond Ovarian Cancer Monotherapy Combination Solid Tumors Endometrial • Monotherapy data continues to be generated in Phase 2 PYNNACLE • Bevacizumab (PSOC) • 2L+ endometrial cancer has the potential to • KRAS inhibitors (NSCLC, Pancreatic, CRC) add ~400 patie
Slide 27: Compelling Efficacy Profile and Defined Registrational Path for Rezatapopt
Compelling Efficacy Profile and Defined Registrational Path for Rezatapopt In the Phase 2 PYNNACLE trial interim data, rezatapopt demonstrated an ORR of 46% in ovarian cancer with a median DoR of 10 months1 FDA feedback supports an initial registrational opportunity in platinum-resistant or refracto
PMV Pharmaceuticals — Investor Presentation (September 2026) on 6ix